antifungal oxidosqualene cyclase inhibitors (AstraZeneca/Trine Pharmaceuticals)

N/A

Report date: 2025/03/14 20:00:48
NME

Base Information

Drug Nameantifungal oxidosqualene cyclase inhibitors (AstraZeneca/Trine Pharmaceuticals)
Drug Alias Nameantifungal oxidosqualene cyclase inhibitors (AstraZeneca/Essential Therapeutics)antifungal oxidosqualene cyclase inhibitors (AstraZeneca/Microcide)pyridine-based squalene synthase inhibitors (Zeneca)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIsomerases inhibitors
TargetsIsomerases
Therapy Area/IndicationsMycoses
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMicrocide Pharmaceuticals IncAstrazeneca PlcTrine Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsMycoses

Other Information

ATC CodeN/A
Related LinksN/A